-
-
-
-
-
-
-
Xilio Therapeutics, Inc. (XLO) Misses Q3 EPS by 6c
-
-
-
-
-
-
-
Xilio Therapeutics (XLO) Issues Q3 Pipeline and Business Updates
-
-
-
-
-
-
-
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
-
-
-
-
-
-
-
Xilio Therapeutics (XLO) Announces Pipeline and Business Updates, Reports Q3
-
-
-
-
-
-
-
Xilio Therapeutics Reports Pipeline and Business Highlights and First Quarter 2022 Financial Results
-
-
-
-
-
-
1,198,550 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

